At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TSHA Taysha Gene Therapies, Inc.
Not Yet Opened 05-28 16:00:00 EDT
3.25
+0.01
+0.31%
盘后3.15
-0.10-3.08%
19:41 EDT
High3.30
Low3.14
Vol1.70M
Open3.24
D1 Closing3.24
Amplitude4.78%
Mkt Cap607.81M
Tradable Cap346.97M
Total Shares187.02M
T/O5.49M
T/O Rate1.60%
Tradable Shares106.76M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.